Revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Adaptimmune Therapeutics PLC (ADAPY)
Price$0.02265Cached quote
Net income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Free cash flow
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Total cash / debt
CashTotal debt
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Financial statements
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $178.0M | $60.3M | $27.1M | $6.1M | $4.0M | $1.1M | $59.5M | $37.8M | $14.2M | $9.9M | $825,000 |
| Gross profit | $178.0M | $60.3M | $27.1M | — | — | — | — | — | — | — | — |
| Gross margin | 99.96% | 100.00% | 100.00% | — | — | — | — | — | — | — | — |
| Research & development | $149.1M | $126.5M | $127.7M | $111.1M | $91.6M | $97.5M | $98.3M | $87.4M | $63.8M | $24.1M | $9.6M |
| Operating expenses | $246.8M | $200.0M | $191.1M | $168.4M | $137.4M | $140.9M | $141.9M | $118.5M | $87.0M | $34.5M | $12.3M |
| Operating income | −$68.8M | −$139.7M | −$164.0M | −$162.2M | −$133.4M | −$139.8M | −$82.4M | −$80.7M | −$72.8M | −$24.6M | −$11.5M |
| Operating margin | −38.62% | −231.82% | −603.97% | −2,638.58% | −3,370.52% | −12,457.22% | −138.42% | −213.20% | −512.74% | −249.63% | −1,396.48% |
| EBITDA | −$57.5M | −$129.9M | −$157.9M | −$155.7M | −$125.8M | −$131.8M | −$74.6M | −$75.2M | −$69.5M | −$23.9M | −$11.3M |
| EBITDA margin | −32.32% | −215.49% | −581.59% | −2,531.78% | −3,178.65% | −11,743.32% | −125.29% | −198.87% | −489.60% | −242.18% | −1,367.39% |
| Net income | −$70.8M | −$113.9M | −$165.5M | −$158.1M | −$130.1M | −$137.2M | −$95.5M | −$70.1M | −$71.6M | −$22.1M | −$11.6M |
| Net profit margin | −39.78% | −188.90% | −609.46% | −2,570.99% | −3,286.81% | −12,225.04% | −160.51% | −185.39% | −504.15% | −223.46% | −1,406.18% |
| Basic EPSper basic share | -$0.05 | -$0.09 | -$0.17 | -$0.17 | -$0.15 | -$0.22 | -$0.16 | -$0.13 | -$0.17 | -$0.17 | -$0.08 |
| Diluted EPSper diluted share | -$0.05 | -$0.09 | -$0.17 | -$0.17 | -$0.15 | -$0.22 | -$0.16 | -$0.13 | -$0.17 | -$0.17 | -$0.08 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
EcoR1 Capital, LLC | 358.67M |
Bertrand William C JR | 986.35K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Sep 2, 2025Form 4 | Wood GavinChief Financial Officer | SellOrdinary Shares with a nominal value of GBP0.001 per share | 96.0K | $0.01 | $960.00 | 0 |
| Aug 28, 2025Form 4 | Bertrand William C JRChief Operating Officer | SellOrdinary Shares with a nominal value of GBP0.001 per share | 207.0K | $0.01 | $2.1K | 986.4K |
| Aug 18, 2025Form 4 | Behbahani AliDirector | SellOrdinary Shares with a nominal value of 0.001 GBP per share · indirect | 14.67M | $0.01 | $146.7K | 0 |
| Aug 15, 2025Form 4 | Behbahani AliDirector | SellOrdinary Shares with a nominal value of 0.001 GBP per share · indirect | 4.83M | $0.01 | $48.3K | 14.67M |
| Jul 30, 2025Form 4 | EcoR1 Capital, LLCTenPercentOwner | SellOrdinary Shares · indirect | 27.43M | $0.10 | $2.74M | 100.37M |